Physician profile
Chukwuma E Eze
NPI 1154419521
$1,581.53
in general payments reported to CMS, 2019-2025
24 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $152 · 2021: $66.51 · 2022: $336 · 2023: $294 · 2024: $267 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.84 |
| Education | $134.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $192.43 | 2019-2024 | |
| Travere Therapeutics, INC. | $161.81 | 2022-2024 | |
| Renalytix Ai, INC. | $158.86 | 2022-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Bayer Healthcare Pharmaceuticals INC. | $157.96 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $141.17 | 2019-2024 | Rayaldee |
| Nxstage Medical, INC. | $120.23 | 2020-2023 | Nxstage System One, Liberty Select Cycler |
| Novartis Pharmaceuticals Corporation | $88.09 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $66.80 | 2021-2024 | Lupkynis |
| Vifor Pharma, INC. | $59.94 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $55.99 | 2019-2024 | |
| Calliditas Therapeutics US INC. | $54.93 | 2023-2025 | Tarpeyo |
| Amgen INC. | $53.35 | 2022-2025 | Tavneos |
| Horizon Therapeutics Plc | $44.92 | 2019-2023 | Krystexxa |
| Bard Peripheral Vascular, INC. | $40.68 | 2025 | Covera |
| Ani Pharmaceuticals, INC. | $38.73 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $23.41 | 2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.67 | 2025 | Jardiance |
| Angiodynamics, INC. | $18.41 | 2023 | Angiodynamics |
| Mallinckrodt Enterprises LLC | $17.67 | 2019 | |
| Daiichi Sankyo INC. | $15.18 | 2021 | |
| Novo Nordisk INC | $14.26 | 2025 | Ozempic |
| Genentech USA, INC. | $13.64 | 2019 | |
| Medtronic, INC. | $11.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chukwuma Eze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.